share_log

SC 13G: Statement of acquisition of beneficial ownership by individuals-Sir Marc Feldmann(8.6%)

SC 13G: Statement of acquisition of beneficial ownership by individuals-Sir Marc Feldmann(8.6%)

SC 13G：超过5%持股股东披露文件-Sir Marc Feldmann(8.6%)
美股SEC公告 ·  10/19 05:04

Moomoo AI 已提取核心信息

On September 5, 2024, Sir Marc Feldmann filed a Schedule 13G with the United States Securities and Exchange Commission (SEC), indicating a significant ownership stake in 180 Life Sciences Corp. The filing revealed that Feldmann holds 90,532 shares of the company's common stock, which includes options to purchase an additional 20,000 shares. As of the filing date, this represented 8.6% of the company's class of securities. However, by October 17, 2024, his percentage ownership decreased to 4.5%. The filing was made in accordance with Rule 13d-1(b) and Rule 13d-1(c), and Feldmann certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer. Sir Marc Feldmann, a UK and Australian citizen, is known for his contributions to the field of immunology and has a principal business address in London, UK.
On September 5, 2024, Sir Marc Feldmann filed a Schedule 13G with the United States Securities and Exchange Commission (SEC), indicating a significant ownership stake in 180 Life Sciences Corp. The filing revealed that Feldmann holds 90,532 shares of the company's common stock, which includes options to purchase an additional 20,000 shares. As of the filing date, this represented 8.6% of the company's class of securities. However, by October 17, 2024, his percentage ownership decreased to 4.5%. The filing was made in accordance with Rule 13d-1(b) and Rule 13d-1(c), and Feldmann certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer. Sir Marc Feldmann, a UK and Australian citizen, is known for his contributions to the field of immunology and has a principal business address in London, UK.
2024年9月5日，马克·费尔德曼爵士向美国证券交易委员会（SEC）提交了13G表，表明他在180 Life Sciences Corp拥有重要的所有权。申报显示，费尔德曼持有该公司普通股的90,532股，其中包括购买额外20,000股的期权。截至申报日期，这代表了公司证券类别的8.6%。然而，到2024年10月17日，他的持股比例下降至4.5%。此次申报是根据13d-1（b）条和13d-1（c）条进行的，费尔德曼证实这些股份并非为了改变或影响发行者的控制权。马克·费尔德曼爵士是英国和澳大利亚公民，以他在伦敦的主要业务地址而闻名，他对免疫学领域的贡献有目共睹。
2024年9月5日，马克·费尔德曼爵士向美国证券交易委员会（SEC）提交了13G表，表明他在180 Life Sciences Corp拥有重要的所有权。申报显示，费尔德曼持有该公司普通股的90,532股，其中包括购买额外20,000股的期权。截至申报日期，这代表了公司证券类别的8.6%。然而，到2024年10月17日，他的持股比例下降至4.5%。此次申报是根据13d-1（b）条和13d-1（c）条进行的，费尔德曼证实这些股份并非为了改变或影响发行者的控制权。马克·费尔德曼爵士是英国和澳大利亚公民，以他在伦敦的主要业务地址而闻名，他对免疫学领域的贡献有目共睹。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Tonix Pharmaceuticals
    TNXP
    -- 0.5223
    Sagimet Biosciences
    SGMT
    -- 5.540
    Sangamo Therapeutics
    SGMO
    -- 2.555
    Viridian Therapeutics
    VRDN
    -- 21.680
    Edgewise Therapeutics
    EWTX
    -- 33.150

    解锁榜首股票